More Top Stories🔒 SSL Verified
Live Data Status: |News & Media
Welcome to the detailed analysis for ascopost.com. This domain is officially recognized as TAP Homepage - The ASCO Post. According to their official web presence, their primary focus is: "Detailed SEO and authority metrics for ascopost.com. Ascopost currently holds an estimated domain authority score of 81/100 in the .COM namespace based on our global index mapping.".
Table of Contents
- Tech Stack
- Cloudflare
- Link Profile
- Internal Pages: 92Outbound Links: 13
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$691
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- ascopost.comAvailable
- ascopost.netAvailable
- ascopost.orgAvailable
- ascopost.ioAvailable
- ascopost.coTaken
- ascopost.aiTaken
Content Snippets from ascopost.com
"Findings from a substudy of the phase III PROTEUS trial provided further support for the use of perioperative apalutamide and androgen-deprivation therapy (ADT) before and after surgery for patients with high-risk localized and locally advanced prostate cancer, according to results presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA53). During the meeting, Alberto Briganti, MD, PhD, Professor of Urology at Vita-Salute San Raffaele University in Milan, Italy, presented the results of the substudy."
"Patients with advanced melanoma achieved deep and durable responses after receiving the tumor-infiltrating lymphocyte (TIL) therapy lifileucel alongside the immune checkpoint inhibitor pembrolizumab as a first-line treatment, according to results from a new clinical trial. Approximately two-thirds (62.5%) of patients saw their tumors shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment."
"Sacituzumab tirumotecan extended both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract LBA11). A report of the findings was also simultaneously published in The Lancet."
"Breast cancer screening with digital breast tomosynthesis plus synthesized two-dimensional mammography resulted in fewer invasive interval breast cancers over 2 years than standard digital mammography, although the difference did not reach statistical significance. Weigel et al reported the 24-month follow-up results of the randomized TOSYMA trial in The Lancet Oncology."
Key Topics & Focus Areas for ascopost.com:
Sponsored Content
By comparing ascopost.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to ascopost.com.
Frequently Asked Questions
Is ascopost.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of ascopost.com?
As of November 2, 2026, ascopost.com holds an estimated domain authority score of 36/100 based on our VisitRank tracking algorithms.
What are the top alternatives to ascopost.com?
You can find the best alternatives and similar sites to ascopost.com in our explore section, which includes competitors in the News & Media sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for ascopost.com:
acsopost.comasopost.comasscopost.comescopost.comascopost.comaacopost.comawcopost.com